Lesley P. Kahl
Brentford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 31, 2024
A phase I, first-in-human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937.
Journal: Pharmacology research & perspectives
Published: February 28, 2023
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Journal: British journal of clinical pharmacology
Published: May 09, 2022
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 15, 2021
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: July 18, 2020
Changes in inflammatory biomarkers in SWORD-1 and SWORD-2 studies - Authors' reply.
Journal: The lancet. HIV
Published: December 20, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Journal: The lancet. HIV
Published: November 21, 2018
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
Journal: AIDS (London, England)
Published: December 15, 2017
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Journal: Lancet (London, England)
Published: August 04, 2017
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
Journal: Lupus
Published: April 09, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026